660 related articles for article (PubMed ID: 32366291)
21. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
Yoon HY; Kim DS; Song JW
Respiration; 2019; 97(3):242-251. PubMed ID: 30332670
[TBL] [Abstract][Full Text] [Related]
22. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
23. Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study.
Suraj KP; Kumar NK; Jyothi E; Narayan KV; Biju G
J Assoc Physicians India; 2016 May; 64(5):36-41. PubMed ID: 27735147
[TBL] [Abstract][Full Text] [Related]
24. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
Lee EG; Lee TH; Hong Y; Ryoo J; Heo JW; Gil BM; Kang HS; Kwon SS; Kim YH
PLoS One; 2021; 16(12):e0261684. PubMed ID: 34941933
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
[TBL] [Abstract][Full Text] [Related]
26. The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study.
Hanta I; Cilli A; Sevinc C
Adv Ther; 2019 May; 36(5):1126-1131. PubMed ID: 30900199
[TBL] [Abstract][Full Text] [Related]
27. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.
Dhooria S; Agarwal R; Sehgal IS; Prasad KT; Muth V; Garg M; Bal A; Aggarwal AN; Behera D
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):148-157. PubMed ID: 33093778
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
[TBL] [Abstract][Full Text] [Related]
29. Pirfenidone improves survival in IPF: results from a real-life study.
Margaritopoulos GA; Trachalaki A; Wells AU; Vasarmidi E; Bibaki E; Papastratigakis G; Detorakis S; Tzanakis N; Antoniou KM
BMC Pulm Med; 2018 Nov; 18(1):177. PubMed ID: 30470213
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
31. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
[TBL] [Abstract][Full Text] [Related]
32. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
Chaudhuri N; Duck A; Frank R; Holme J; Leonard C
Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005
[TBL] [Abstract][Full Text] [Related]
33. [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis].
Bonella F; Wessendorf TE; Costabel U
Dtsch Med Wochenschr; 2013 Mar; 138(11):518-23. PubMed ID: 23423955
[TBL] [Abstract][Full Text] [Related]
34. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lancaster LH; de Andrade JA; Zibrak JD; Padilla ML; Albera C; Nathan SD; Wijsenbeek MS; Stauffer JL; Kirchgaessler KU; Costabel U
Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29212837
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients.
Chung MP; Park MS; Oh IJ; Lee HB; Kim YW; Park JS; Uh ST; Kim YS; Jegal Y; Song JW
Adv Ther; 2020 May; 37(5):2303-2316. PubMed ID: 32297284
[TBL] [Abstract][Full Text] [Related]
36. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Anderson A; Shifren A; Nathan SD
Expert Opin Drug Saf; 2016 Jul; 15(7):975-82. PubMed ID: 27177012
[TBL] [Abstract][Full Text] [Related]
37. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.
Potts J; Yogaratnam D
Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.
Valeyre D; Albera C; Bradford WZ; Costabel U; King TE; Leff JA; Noble PW; Sahn SA; du Bois RM
Respirology; 2014 Jul; 19(5):740-7. PubMed ID: 24836849
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.
Delanote I; Wuyts WA; Yserbyt J; Verbeken EK; Verleden GM; Vos R
BMC Pulm Med; 2016 Nov; 16(1):156. PubMed ID: 27863518
[TBL] [Abstract][Full Text] [Related]
40. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.
Ogura T; Azuma A; Inoue Y; Taniguchi H; Chida K; Bando M; Niimi Y; Kakutani S; Suga M; Sugiyama Y; Kudoh S; Nukiwa T
Respir Investig; 2015 Sep; 53(5):232-41. PubMed ID: 26344613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
